ダウンロード数: 333

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
onc.2014.28.pdf14.77 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorKumagai, Yukaen
dc.contributor.authorHonda, Naokien
dc.contributor.authorNakasyo, Eijien
dc.contributor.authorKamioka, Yujien
dc.contributor.authorKiyokawa, Etsukoen
dc.contributor.authorMatsuda, Michiyukien
dc.contributor.alternative松田, 道行ja
dc.date.accessioned2015-07-24T01:08:10Z-
dc.date.available2015-07-24T01:08:10Z-
dc.date.issued2015-02-17-
dc.identifier.issn0950-9232-
dc.identifier.urihttp://hdl.handle.net/2433/198805-
dc.description.abstractHuman epidermal growth factor receptor2/Neu, which is overexpressed in about 30% of human breast cancers, transduces growth signals in large part via the Ras-Raf-MEK-ERK pathway. Nevertheless, it is a matter of controversy whether high ERK activity in breast cancer tissues correlates with better or worse prognosis, leaving the role of ERK activity in the progression of breast cancers unresolved. To address this issue, we live-imaged ERK activity in mammary tumors developed in mouse mammary tumor virus-Neu transgenic mice, which had been crossed with transgenic mice expressing a Förster resonance energy transfer biosensor for ERK. Observation of the tumor by two-photon microscopy revealed significant heterogeneity in ERK activity among the mammary tumor cells. The level of ERK activity in each cell was stable up to several hours, implying a robust mechanism that maintained the ERK activity within a limited range. By sorting the mammary tumor cells on the basis of their ERK activity, we found that ERK(high) cells less efficiently generated tumorspheres in vitro and tumors in vivo than did ERK(low) cells. In agreement with this finding, the expressions of the cancer stem cell markers CD49f, CD24 and CD61 were decreased in ERK(high) cells. These observations suggest that high ERK activity may suppress the self-renewal of mammary cancer stem cells.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherNature Publishing Groupen
dc.rights© 2015 Macmillan Publishers Limited.en
dc.rightsThis is not the published version. Please cite only the published version.en
dc.rightsこの論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。ja
dc.subject.meshAnimalsen
dc.subject.meshAntineoplastic Agents/pharmacokineticsen
dc.subject.meshBenzamides/pharmacokineticsen
dc.subject.meshComputer Systemsen
dc.subject.meshDiphenylamine/analogs & derivativesen
dc.subject.meshDiphenylamine/pharmacokineticsen
dc.subject.meshExtracellular Signal-Regulated MAP Kinases/antagonists & inhibitorsen
dc.subject.meshExtracellular Signal-Regulated MAP Kinases/metabolismen
dc.subject.meshFemaleen
dc.subject.meshFluorescence Resonance Energy Transferen
dc.subject.meshGenes, erbB-2en
dc.subject.meshMammary Neoplasms, Experimental/geneticsen
dc.subject.meshMammary Neoplasms, Experimental/metabolismen
dc.subject.meshMammary Neoplasms, Experimental/pathologyen
dc.subject.meshMammary Tumor Virus, Mouse/geneticsen
dc.subject.meshMiceen
dc.subject.meshMice, Transgenicen
dc.subject.meshMolecular Imaging/methodsen
dc.subject.meshNeoplasm Metastasisen
dc.subject.meshProtein Kinase Inhibitors/pharmacokineticsen
dc.titleHeterogeneity in ERK activity as visualized by in vivo FRET imaging of mammary tumor cells developed in MMTV-Neu mice.en
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.ncidAA10687380-
dc.identifier.jtitleOncogeneen
dc.identifier.volume34-
dc.identifier.issue8-
dc.identifier.spage1051-
dc.identifier.epage1057-
dc.relation.doi10.1038/onc.2014.28-
dc.textversionauthor-
dc.startdate.bitstreamsavailable2014/09/17-
dc.identifier.pmid24632612-
dcterms.accessRightsopen access-
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。